Assessment of a DNA-PK Inhibitor as a Chemo-potentiating Agent in Osteosarcoma

被引：0
|
作者：
O'Reilly, E. [1 ]
Vormoor, B. [1 ]
Kyle, S. [1 ]
Newell, H. [1 ]
机构：
[1] No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72087-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
289
引用
收藏
页码：88 / 89
页数：2
相关论文
共 50 条
  • [41] Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigation
    Mortensen, D. S.
    Fultz, K. E.
    Xu, W.
    Tsuji, T.
    Hickman, M.
    Abbasian, M.
    Khambatta, G.
    Cathers, B.
    Worland, P.
    Moghaddam, M. F.
    Apuy, J.
    Richardson, S.
    Elsner, J.
    Shevlin, G.
    Perrin-Ninkovic, S.
    Canan, S.
    Raymon, H. K.
    Narla, R. K.
    Peng, S.
    Sankar, S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 150 - 150
  • [42] Induced macropinocytosis by DNA-PK inhibitor for KRAS mutant cancer targeting of albumin-binding peptide drug conjugate
    Kim, Ha Rin
    Park, Seong Jin
    Mudhibadhi, Moyo Knowledge
    Park, Jae Hee
    Byun, Youngro
    CANCER RESEARCH, 2023, 83 (07)
  • [43] A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
    Romesser, Paul B.
    Capdevila, Jaume
    Garcia-Carbonero, Rocio
    Philip, Tony
    Martos, Carlos Fernandez
    Tuli, Richard
    Rodriguez-Gutierrez, Almudena
    Kuipers, Mirjam
    Becker, Andreas
    Coenen-Stass, Anna
    Sarholz, Barbara
    You, Xiaoli
    Miller, Eric D.
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 695 - 702
  • [44] Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
    Hannah C. Wise
    Gopakumar V. Iyer
    Kathleen Moore
    Sarah M. Temkin
    Sarah Gordon
    Carol Aghajanian
    Rachel N. Grisham
    Scientific Reports, 9
  • [45] Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
    Wise, Hannah C.
    Iyer, Gopakumar V.
    Moore, Kathleen
    Temkin, Sarah M.
    Gordon, Sarah
    Aghajanian, Carol
    Grisham, Rachel N.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [46] DNA-PK inhibition augment the cancer specific cytotoxicity of mitotic MTH1 inhibitor OXC-101
    Danda, Akhilesh Nagesh
    Gad, Helge
    Scobie, Martin
    Martinez-Lopez, Laura
    Carrillo, Nuria Pastor
    Orta, Manuel Luis
    Helleday, Thomas
    Berglund, Ulrika Warpman
    Sanjiv, Kumar
    CANCER RESEARCH, 2023, 83 (07)
  • [47] AZD-7648, a DNA-PK Inhibitor, Induces DNA Damage, Apoptosis, and Cell Cycle Arrest in Chronic and Acute Myeloid Leukemia Cells
    Lapa, Beatriz Santos
    Costa, Maria Ines
    Figueiredo, Diana
    Jorge, Joana
    Alves, Raquel
    Monteiro, Ana Raquel
    Serambeque, Beatriz
    Laranjo, Mafalda
    Botelho, Maria Filomena
    Carreira, Isabel Marques
    Sarmento-Ribeiro, Ana Bela
    Goncalves, Ana Cristina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (20)
  • [48] Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries
    Leahy, JJJ
    Golding, BT
    Griffin, RJ
    Hardcastle, IR
    Richardson, C
    Rigoreau, L
    Smith, GCM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (24) : 6083 - 6087
  • [49] TORK/DNA-PK inhibitor CC-115 is effective as a single agent in a subset of glioblastoma patient-derived cancer stem cells and xenografts and potentiates temozolomide therapy
    Bergman, Kimberly
    Irtenkauf, Susan M.
    Hasselbach, Laura A.
    Mueller, Claudius
    Petricoin, Emanuel
    Raymon, Heather
    Mikkelsen, Tom
    Decarvalho, Ana C.
    CANCER RESEARCH, 2015, 75
  • [50] DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors
    Wang, Taixiang
    Kyle, Alastair H.
    Baker, Jennifer H. E.
    Liu, Nannan A.
    Banath, Judit P.
    Teymori, Sevin
    Minchinton, Andrew I.
    DNA REPAIR, 2024, 139
12345